ATC Group: N02CA01 Dihydroergotamine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N02CA01 in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N02 Analgesics
3 N02C Antimigraine preparations
4 N02CA Ergot alkaloids
5 N02CA01 Dihydroergotamine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
NASAL - Nasal 1 mg
ORAL - Oral 4 mg
PAREN - Parenteral 4 mg

Active ingredients in N02CA01

Active Ingredient Description
Dihydroergotamine

Dihydroergotamine binds with high affinity to 5-HT1DĪ± and 5-HT1DĪ² receptors. It also binds with high affinity to serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors. The therapeutic activity of dihydroergotamine in migraine is generally attributed to the agonist effect at 5-HT1D receptors.

Related product monographs

Title Information Source Document Type  
MIGRANAL Nasal spray FDA, National Drug Code (US) MPI, US: SPL/Old

Medicines in this ATC group

United States (US)

Austria (AT)

Canada (CA)

France (FR)

South Africa (ZA)

Tunisia (TN)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.